

**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Kimme Hyrich
Rik Lories
Iain McInnes
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)

Disclaimer: The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

Copyright: © 2021 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

Editorials

1249 SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future
L Winthrop, R J Whitley, D Aletaha

1252 Call for emergency action to limit global temperature increases, restore biodiversity and protect health

L Atwoli, A H Baqui, T Benfield, R Bosurgi, F Godlee, S Hancocks, R Horton, L Laybourn-Langton, C A Monteiro, I Norman, K Patrick, N Praities, M GM O Rieker, E J Rubin, P Sahni, R Smith, N J Talley, S Turale, D Vázquez

Reviews

1255 Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases

M A Friedman, J R Curtis, K L Winthrop

1266 Message from the new EULAR President and Steering Group

A Iagnocco, D Aletaha, X Baraliakos, I B McInnes

1268 Preclinical models of arthritis for studying immunotherapy and immune tolerance

G R Meehan, R Thomas, S Al Khabouri, P Wehr, C MU Hilkens, D C Wraith, D Sieghart, M Bonelli, G Nagy, P Garside, D F Tough, H D Lewis, J M Brewer

Recommendations

1278 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis

E Nikiphorou, E J F Santos, A Marques, P Böhm, J W J Bijlsma, C I Daien, B A Esbensen, R J O Ferreira, G E Fragoulis, P Holmes, H McBain, G S Metsios, R H Moe, T A Stamm, A de Thurah, C Zabalan, L Carmona, A Bosworth

1286 EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis

K Mankia, H J Siddle, A Kerschbaumer, D Alpizar Rodriguez, A I Catrina, J D Cañete, A P Cope, C I Daien, K D Deane, H El Gabalawy, A Finckh, V M Holers, M Koloumas, F Ometto, K Raza, C Zabalan, A van der Helm-van Mil, D van Schaardenburg, D Aletaha, P Emery

1299 EULAR recommendations for intra-articular therapies

J Uson, S C Rodriguez-García, R Castellanos-Moreira, T W O'Neill, M Doherty, M Boesen, H Pandit, I Möller Parera, V Vardanyan, L Terslev, W U Kampen, M-A D'Agostino, F Berenbaum, E Nikiphorou, I A Pitsillidou, J de la Torre-Aboki, L Carmona, E Naredo

Epidemiology

1306 Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

U M Geisen, D K Berner, F Tran, M Sümbül, L Vullriede, M Ciripoi, H M Reid, A Schaffarzyk, A C Longardt, J Franzensburg, P Hoff, J H Schirmer, R Zeumer, A Friedrichs, A Steinbach, C Knies, R DH Markewitz, P J Morrison, S Gerdes, S Schreiber, B F Hoyer

1312 SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases

D Simon, K Tascilar, F Fagni, G Krönke, A Kleyer, C Meder, R Atreya, M Leppkes, A E Kremer, A Ramming, M L Pachowsky, F Schuch, M Ronneberger, S Kleinert, A J Hueber, K Manger, B Manger, C Berking, M Stücherling, M F Neurath, G Schett

1317 Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2

Y Braun-Moscovici, M Kaplan, M Braun, D Markovits, S Giryas, K Toledano, Y Tavor, K Dolnikov, A Balbir-Gurman

1322 Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression

M Prendecki, C Clarke, H Edwards, S McIntyre, P Mortimer, S Gleeson, P Martin, T Thomson, P Randell, A Shah, A Singanayagam, L Lightstone, A Cox, P Kelleher, M Willicombe, S P McAdoo

MORE CONTENTS ►

EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>



Member since 2008

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

- 1330** Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
V Furer, T Eviatar, D Zisman, H Peleg, D Paran, D Levartovsky, M Zisapel, O Elalouf, I Kaufman, R Meidan, A Broyde, A Polachek, J Wollman, I Litinsky, K Meridor, H Nochomovitz, A Silberman, D Rosenberg, J Feld, A Haddad, T Gazzit, M Elias, N Higazi, F Kharouf, G Shefer, O Sharon, S Pel, S Nevo, O Elkayam
- 1339** Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
R H Haberman, R Herati, D Simon, M Samanovic, R B Blank, M Tuen, S B Korolov, R Atreya, K Tascilar, J R Allen, R Castillo, A R Cornelius, P Rackoff, G Solomon, S Adhikari, N Azar, P Rosenthal, P Izmirly, J Samuels, B Golden, S M Reddy, M F Neurath, S B Abramson, G Schett, M J Mulligan, J U Scher
- 1345** SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity
D Mrak, S Tobudic, M Koblischke, M Graninger, H Radner, D Sieghart, P Hofer, T Perkmann, H Haslacher, R Thalhammer, S Winkler, S Blüml, K Stiasny, J H Aberle, J S Smolen, L X Heinz, D Aletaha, M Bonelli
- 1357** Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases
R Spiera, S Jinich, D Jannat-Khah
- 1359** Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report
B Golding, Y Lee, H Golding, S Khurana
- 1361** Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response
F N Albach, G R Burmester, R Biesen
- 1362** Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation
M T H F Janssen, S Ramiro, R B M Landewé, C Magro-Checa, R L M Mostard
- 1364** Prospective study into COVID-19-like symptoms in patients with and without immune-mediated inflammatory diseases or immunomodulating drugs
L van Ouwkerke, A E van der Meulen-de Jong, M K Ninaber, Y K O Teng, T W J Huizinga, C F Allaart
- 1365** Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases
T P-Y Chiang, C M Connolly, J A Ruddy, B J Boyarsky, J L Alejo, W A Werbel, A Massie, L Christopher-Stine, J Garonzik-Wang, D L Segev, J J Paik
- 1352** Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City
M Barbhuiya, J M Levine, V P Bykerk, D Jannat-Khah, L A Mandl
- 1354** SARS-CoV-2 vaccination after stem cell transplantation for scleroderma
D Rimar, G Slobodin, A Paz, I Henig, T Zuckerman
- 1355** SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response
M M Bonelli, D Mrak, T Perkmann, H Haslacher, D Aletaha

Letters

- 1351** High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases
J A Ruddy, C M Connolly, B J Boyarsky, W A Werbel, L Christopher-Stine, J Garonzik-Wang, D L Segev, J J Paik
- Electronic pages**
- e156** Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs'
S Bugatti, S Balduzzi, L De Stefano, A Manzo, B Xoxi, L Bogliolo, S Monti, P Delvino, C Montecucco
- e157** Response to: 'Correspondence on 'EULAR December 2020 View points on SARS-CoV-2 vaccination in patients with RMDs'' by Bugatti *et al*
J W J Bijlsma, on behalf of EULAR COVID-19 Task Force

- e158** Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’
C Salviani, F Scolari, F Alberici
- e159** Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’
G A Ramirez, E Della-Torre, L Moroni, M-R Yacoub, L Dagna, On behalf of the OSR-COVAX study group
- e160** Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’
J Veenstra, J Wang, K McKinnon-Maksimowicz, T Liu, B Zuniga, I Hamzavi, L Zhou, Q-S Mi
- e161** Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’
L Valor-Méndez, K Tascilar, D Simon, J Distler, A Kleyer, G Schett, J Rech
- e162** Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’
T H Westhoff, F S Seibert, M Anft, A Blazquez-Navarro, S Skrzypczyk, A Doevelaar, B Hölzer, K Paniskaki, S Doff, B Wilde, O Witzke, J Braun, U Stervbo, N Babel
- e163** Response to: ‘Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’ by Westhoff *et al*’
M Bonelli, D Aletaha
- e164** Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’ by Bonelli *et al*
C M Connolly, D Koenig, S N Ravi, A Azar, S Kant, M Dalal, J Duchon, P Seo, B Antiochos, J J Paik, D Geetha
- e165** Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’ by Bonelli *et al*
S H Chung, M Wener, A M Bays, H Rahbar, C Morishima, A B Bryan, S L Fink, S Cohen, N S Mani, A Chaudhary, G C Gardner
- e166** Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’ by Bonelli *et al*
M Benucci, A Damiani, M Infantino, M Manfredi, V Grossi, B Lari, F Li Gobbi, P Sarzi Puttini
- e167** Response to: Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’ by Bonelli *et al*
M Bonelli, D Aletaha
- e168** Correspondence on ‘SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists’
G Smerilli, E Cipolletta, E Mosconi, F Francioso, A M Risa, V Maccarrone, D Zompa, A Di Matteo, M Di Carlo, R De Angelis, F Salaffi, E Filippucci, W Grassi
- e169** Response to: ‘Correspondence on ‘SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists’ by Smerilli *et al*’
R Priori, G Pellegrino, S Colafrancesco, C Alessandri, F Ceccarelli, M Di Franco, V Riccieri, R Scrivo, A Sili Scavalli, F R Spinelli, F Conti
- e170** Correspondence on ‘Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries’
S Al Nokhatha, N MacEoin, R Conway
- e171** Response to: ‘Correspondence on ‘Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries’ by Nokhatha *et al*’
C DeJaco, J WJ Bijlsma, F Buttgerit